Third Line/Rescue HIV Treatment Research
- Management of Treatment-Experienced Patients: A Summary of Key CROI 2008 Research (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- New Treatment Paradigms for Treatment-Experienced Patients (November 13, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here.
From Insight Medical Communications Inc.
On TheBodyPRO.com
- New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From TheBodyPRO.com
- Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
[Archived Article]
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
[Archived Article]
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From TheBodyPRO.com
- Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
[Archived Article]
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From TheBodyPRO.com
- Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
[Archived Article]
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
- Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
[Archived Article]
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
- Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from TheBodyPRO.com
- New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
- Salvage Therapy II Think Tank: Regulatory Issues and Challenges in Salvage Therapy (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here.
In Research Initiative/Treatment Action!, from The Center for AIDS
On TheBodyPRO.com
- Salvage Therapy II Think Tank: Integration of Salvage Research Into Existing Networks and Structures (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here.
In Research Initiative/Treatment Action!, from The Center for AIDS
On TheBodyPRO.com
- Salvage Therapy II Think Tank: Proof of Concept Studies/Translational Research; New Hypotheses (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here.
In Research Initiative/Treatment Action!, from The Center for AIDS
On TheBodyPRO.com
- Salvage Therapy II Think Tank: The Future of Salvage Therapy: Monitoring Systems for Patient Outcomes (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here.
In Research Initiative/Treatment Action!, from The Center for AIDS
On TheBodyPRO.com
- Salvage Therapy II Think Tank: Meeting Summary (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here.
In Research Initiative/Treatment Action!, from The Center for AIDS
On TheBodyPRO.com
- Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Single-Drug Interruption May Be Useful in Identifying Still-Active Drugs in Heavily Treated Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Triple-PI Regimens for Rescue Treatment (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
[Archived Article]
To read PDF, click here.
From U.S. Food and Drug Administration
- Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
[Archived Article]
From aidsmap.com
- Risk of Death Following Triple-Class Virological Failure (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Salvage Therapy (September 2003)
[Archived Article]
2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- To Switch or Not to Switch: When Is It a Question? (September 2003)
[Archived Article]
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook
- Ritonavir-Boosted Atazanavir Demonstrates Comparable Viral Load Reduction to Kaletra (August 15, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
[Archived Article]
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Atazanavir in Treatment-Experienced Patients (July 15, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
[Archived Article]
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Atazanavir Resistance: Use as Second- or Third-Line PI Should Not Be Ruled Out (April 1, 2003)
[Archived Article]
Evidence that this drug in development may be more than a first-line treatment.
From aidsmap.com
- Structured Treatment Interruption to Increase Response to Salvage Therapy (Spring 2003)
[Archived Article]
From STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
- The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Salvage Strategies and STI at the 10th Annual Retrovirus Conference (January/February 2003)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
- Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Safety Profile of Tenofovir DF in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- Predictors of Long-Term Response to Therapy Resumption After Treatment Interruption in HIV-1 Infected Patients Failing Antiretroviral Therapy (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- International HIV Workshop on Management of Treatment-Experienced Patients (November 2002)
[Archived Article]
A summary of the workshop's presentations.
In Hopkins HIV Report
- Data From the 14th International AIDS Conference: Treatment-Experienced Patients (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Expert Opinion From Barcelona: For Experienced Folks (September/October 2002)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Dual vs. Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure (July 10, 2002)
[Archived Article]
Adding a second protease inhibitor to a failing regimen brings favorable results, according to a nationwide study.
In Journal of the American Medical Association
- Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Safety Profile of Tenofovir DF in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
- Anti-HIV Therapy Update: STI and Third-Line Therapy (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Selected Highlights From Retrovirus: Medications for the Treatment Experienced (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Management of "Salvage" Antiretroviral Therapy (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Antiretroviral Therapy for Previously Treated Patients (December 2001)
[Archived Article]
Summary of an August 2001 New England Journal of Medicine editorial.
In Body Positive, from Body Positive
- Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Antiviral Activity and Tolerability of PEG-Intron in HIV Patients Failing HAART (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Impact of Treatment Interruption on Plasma Viral Load, CD4 Count and Virtual Phenotypes (Virco) in HIV Patients Who Failed Multiple Courses of Antiretroviral Therapy (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- FDA Discusses Trial Design for Salvage Therapy (April 2001)
[Archived Article]
In TAGline, from Treatment Action Group
On TheBodyPRO.com
- FDA Gives Salvage Therapy Testing a Push Forward (March 23, 2001)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Treatment of Antiretroviral-Experienced Patients: New Data From the 8th Retrovirus Conference (March 1, 2001)
[Archived Article]
In Hopkins HIV Report
- Amprenavir and Ritonavir: Intra-Individual Comparison of Different Doses and Influence of Concomitant NNRTI on Steady-State Pharmacokinetics in HIV-Infected Patients (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Randomized Salvage Therapy With Saquinavir-Ritonavir (SQV-RTV) Versus Saquinavir-Nelfinavir (SQV-NFV) for Highly Experienced HIV-Infected Patients (September 17, 2000)
[Archived Article]
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- New Drugs for the Treatment-Experienced Patient (September 2000)
[Archived Article]
In The PRN Notebook
- Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- Prospective, Multicenter Study of ddI Plus Hydroxyurea Plus Efavirenz Plus Protease Inhibitor Salvage Therapy. One-Year of Follow-Up. (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- Response to Salvage With Efavirenz: Implications for Sequencing Antiretroviral Therapy (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- Responses to Salvage Combination Therapy With Efavirenz in Patients With HIV Who Have Failed Antiretroviral Therapy With a Protease Inhibitor (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug Resistant HIV (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from TheBodyPRO.com
- Conference Coverage: 3rd International Workshop on Salvage Therapy for HIV Infection (Summer 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Advances in Research: Second & Third Line Therapy (September 1999)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Randomized Trial of Abacavir in Combination with Indinavir and Efavirenz in HIV-Infected Patients with NRTI Experience (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Efficacy of the Combination of Stavudine (d4T), Didanosine (ddI), and Nevirapine (NVP) as Initial Antiretroviral Therapy and Following Treatment with HIV-1 Protease Inhibitors (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from TheBodyPRO.com
- Combination d4T and 3TC in Patients with Prior Exposure (February 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- Double Protease Inhibitor Combinations (September 28-October 1, 1997)
[Archived Article]
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- A Study to Evaluate the Clinical and Virologic Efficacy of a Crixivan, DDI, and D4T Combination (September 1997)
[Archived Article]
In The 35th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Druthers, Grim: Tales of Multiply Resistant HIV (February 7, 1997)
[Archived Article]
From Treatment Action Group
- Ritonavir-Saquinavir Combination Therapy in Patients with Advanced HIV Infection (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Viral Resistance (report from the XIth International AIDS Conference) (Summer 1996)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
- More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
